| 2.25 -0.15 (-6.25%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.55 |
1-year : | 4.12 |
| Resists | First : | 3.04 |
Second : | 3.52 |
| Pivot price | 2.93 |
|||
| Supports | First : | 2.25 |
Second : | 1.87 |
| MAs | MA(5) : | 2.49 |
MA(20) : | 2.87 |
| MA(100) : | 3.9 |
MA(250) : | 13.69 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.7 |
D(3) : | 8.7 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 305 | Low : | 1.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HIND ] has closed above bottom band by 4.2%. Bollinger Bands are 14.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.33 - 2.35 | 2.35 - 2.37 |
| Low: | 2.2 - 2.23 | 2.23 - 2.25 |
| Close: | 2.22 - 2.26 | 2.26 - 2.29 |
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.
Tue, 24 Feb 2026
MIT-born Humanyze’s AI HR engine shifts as Livechain takes over operations - Stock Titan
Wed, 18 Feb 2026
Experimental eye drop for uveitis rivals steroids in tests, targets $3B - Stock Titan
Wed, 28 Jan 2026
Vyome Holdings, Inc Announces Key Findings on VT-1953 - TradingView
Tue, 27 Jan 2026
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study - Business Wire
Mon, 29 Dec 2025
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate - Yahoo Finance
Fri, 05 Dec 2025
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.54e+006 (%) |
| Held by Institutions | 42.1 (%) |
| Shares Short | 81 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.63e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 508.9 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 344590 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 189140 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|